247 related articles for article (PubMed ID: 31660121)
1. The safety and tolerability profile of bilastine for chronic urticaria in children.
Papadopoulos NG; Zuberbier T
Clin Transl Allergy; 2019; 9():55. PubMed ID: 31660121
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic spontaneous urticaria with an inadequate response to H1-antihistamines: an expert opinion.
Vestergaard C; Toubi E; Maurer M; Triggiani M; Ballmer-Weber B; Marsland A; Ferrer M; Knulst A; Giménez-Arnau A
Eur J Dermatol; 2017 Feb; 27(1):10-19. PubMed ID: 27882879
[TBL] [Abstract][Full Text] [Related]
3. Bilastine: a new H
Church MK; Labeaga L
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1447-1452. PubMed ID: 28467671
[TBL] [Abstract][Full Text] [Related]
4. Bilastine: new insight into antihistamine treatment.
Ridolo E; Montagni M; Bonzano L; Incorvaia C; Canonica GW
Clin Mol Allergy; 2015; 13(1):1. PubMed ID: 25878559
[TBL] [Abstract][Full Text] [Related]
5. Management of Chronic Spontaneous Urticaria in Routine Clinical Practice Following the EAACI/GA(2)LEN/EDF/WAO Guidelines.
Marín-Cabañas I; Berbegal-de Gracia L; de León-Marrero F; Hispán P; Silvestre JF
Actas Dermosifiliogr; 2017 May; 108(4):346-353. PubMed ID: 28219634
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of switching to bilastine, a histamine H1 receptor antagonist, in patients with chronic spontaneous urticaria (H1-SWITCH): study protocol for a randomized controlled trial.
Fukunaga A; Oda Y; Washio K; Omori T; Kakei Y; Hide M; Nishigori C
Trials; 2020 Jan; 21(1):23. PubMed ID: 31906999
[TBL] [Abstract][Full Text] [Related]
7. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria.
Zuberbier T; Asero R; Bindslev-Jensen C; Walter Canonica G; Church MK; Giménez-Arnau AM; Grattan CEH; Kapp A; Maurer M; Merk HF; Rogala B; Saini S; Sánchez-Borges M; Schmid-Grendelmeier P; Schünemann H; Staubach P; Vena GA; Wedi B
Allergy; 2009 Oct; 64(10):1427-1443. PubMed ID: 19772513
[TBL] [Abstract][Full Text] [Related]
8. The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update.
Zuberbier T; Aberer W; Asero R; Bindslev-Jensen C; Brzoza Z; Canonica GW; Church MK; Ensina LF; Giménez-Arnau A; Godse K; Gonçalo M; Grattan C; Hebert J; Hide M; Kaplan A; Kapp A; Abdul Latiff AH; Mathelier-Fusade P; Metz M; Nast A; Saini SS; Sánchez-Borges M; Schmid-Grendelmeier P; Simons FE; Staubach P; Sussman G; Toubi E; Vena GA; Wedi B; Zhu XJ; Maurer M; ; ; ;
Allergy; 2014 Jul; 69(7):868-87. PubMed ID: 24785199
[TBL] [Abstract][Full Text] [Related]
9. Cardiac safety of second-generation H
Cataldi M; Maurer M; Taglialatela M; Church MK
Clin Exp Allergy; 2019 Dec; 49(12):1615-1623. PubMed ID: 31519068
[TBL] [Abstract][Full Text] [Related]
10. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria.
Zuberbier T; Aberer W; Asero R; Abdul Latiff AH; Baker D; Ballmer-Weber B; Bernstein JA; Bindslev-Jensen C; Brzoza Z; Buense Bedrikow R; Canonica GW; Church MK; Craig T; Danilycheva IV; Dressler C; Ensina LF; Giménez-Arnau A; Godse K; Gonçalo M; Grattan C; Hebert J; Hide M; Kaplan A; Kapp A; Katelaris CH; Kocatürk E; Kulthanan K; Larenas-Linnemann D; Leslie TA; Magerl M; Mathelier-Fusade P; Meshkova RY; Metz M; Nast A; Nettis E; Oude-Elberink H; Rosumeck S; Saini SS; Sánchez-Borges M; Schmid-Grendelmeier P; Staubach P; Sussman G; Toubi E; Vena GA; Vestergaard C; Wedi B; Werner RN; Zhao Z; Maurer M;
Allergy; 2018 Jul; 73(7):1393-1414. PubMed ID: 29336054
[TBL] [Abstract][Full Text] [Related]
11. Experience with bilastine in the management of urticaria: Original Real-world cases of Bilastine In Treatment (ORBIT) in Asia.
Cheong WK; Chan AWM; Ch'ng CC; Chung WH; Gabriel MT; Godse K; Mitthamsiri W; Nguyen HT; Tiongco-Recto M; Nagrale D
Drugs Context; 2022; 11():. PubMed ID: 35371270
[TBL] [Abstract][Full Text] [Related]
12. Treatment of allergic rhinitis and urticaria: a review of the newest antihistamine drug bilastine.
Wang XY; Lim-Jurado M; Prepageran N; Tantilipikorn P; Wang de Y
Ther Clin Risk Manag; 2016; 12():585-97. PubMed ID: 27110120
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria.
Rodríguez M; Vozmediano V; García-Bea A; Novák Z; Yáñez A; Campo C; Labeaga L
Eur J Pediatr; 2020 May; 179(5):801-805. PubMed ID: 31919579
[TBL] [Abstract][Full Text] [Related]
14. An international Delphi study on the burden of allergic rhinoconjunctivitis and urticaria and the role of bilastine among current treatment options.
Church MK; Canonica GW; Kuna P; Maurer M; Mösges R; Novak Z; Papadopoulos NG; Rodriguez Del Rio P;
Expert Rev Clin Immunol; 2023; 19(7):813-820. PubMed ID: 37191185
[TBL] [Abstract][Full Text] [Related]
15. Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
Novák Z; Yáñez A; Kiss I; Kuna P; Tortajada-Girbés M; Valiente R;
Pediatr Allergy Immunol; 2016 Aug; 27(5):493-8. PubMed ID: 26918853
[TBL] [Abstract][Full Text] [Related]
16. One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases.
Yagami A; Furue M; Togawa M; Saito A; Hide M
J Dermatol; 2017 Apr; 44(4):375-385. PubMed ID: 27862227
[TBL] [Abstract][Full Text] [Related]
17. A case series study of eighty-five chronic spontaneous urticaria patients referred to a tertiary care center.
Kibsgaard L; Lefevre AC; Deleuran M; Vestergaard C
Ann Dermatol; 2014 Feb; 26(1):73-8. PubMed ID: 24648689
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of the updosing of second-generation non-sedating H1 antihistamines in children with chronic spontaneous urticaria.
Sarti L; Barni S; Giovannini M; Liccioli G; Novembre E; Mori F
Pediatr Allergy Immunol; 2021 Jan; 32(1):153-160. PubMed ID: 32745323
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness, safety, and tolerability of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic spontaneous urticaria: A double-blind, parallel group, randomized controlled trial.
Podder I; Das A; Ghosh S; Biswas D; Sengupta S; Chowdhury SN
Dermatol Ther; 2020 Nov; 33(6):e13946. PubMed ID: 32618048
[TBL] [Abstract][Full Text] [Related]
20. Chronic Urticaria: Following Practice Guidelines.
Westby EP; Lynde C; Sussman G
Skin Therapy Lett; 2018 May; 23(3):1-4. PubMed ID: 29772036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
